
|Podcasts|November 13, 2009
Regulatory and Safety: Obesity Drugs
Advertisement
Diabetes & Obesity Series
Safety and Regulatory Aspects of Obesity Drugs
Subscribe to RSS feed of this series
Dr. David Orloff
Executive Director of Regulatory Affairs
Medpace
Dr. Orloff discusses the current and potential future regulatory issues for obesity and diabetes drugs, how FDA and industry is moving toward levels of safety for these drug classes.
Others in the Series
Diabetes Resources
- Articles, Multimedia
Diabetes Drugs in Development, 2009
Associations and Societies
Clinical Trials
Obesity Resources
Articles, Multimedia
Associations and Societies
Clinical Trials
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Beyond Compliance: AJNA BioSciences' Joel Stanley on Bringing Botanical Medicine Through the FDA Pathway
2
Where AI Is Delivering Real Value in Clinical Trial Payments Right Now
3
ACT Brief: AI in Invoice Processing, Botanical Medicines and FDA Pathways, and Connected Trial Finance Systems
4
From Doing to Reviewing: How a Connected Ecosystem Streamlines Clinical Trial Finance
5



